Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

65.69 +1.54 (+2.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 Next >
10 Analysts Have This to Say About Merus
 
Via Benzinga
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
 
Via Benzinga
Where Merus Stands With Analysts
 
Via Benzinga
Expert Ratings for Merus
 
Via Benzinga
Analyst Expectations for Merus's Future
 
Via Benzinga
Where Merus Stands With Analysts
 
Via Benzinga
Merus Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Recap: Merus Q1 Earnings
 
Via Benzinga
Analyst Boosts Merus Price Target As AACR Updates Meaningfully De-Risk Its Head & Cancer Therapy
 
Via Benzinga
The Latest Analyst Ratings for Merus
 
Via Benzinga
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
From Merus N.V.
Via GlobeNewswire
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
From Merus N.V.
Via GlobeNewswire
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
From Merus N.V.
Via GlobeNewswire
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
From Merus N.V.
Via GlobeNewswire
7 Stocks That Wall Street Analysts Are Loving in May
Though not perfect, an analyst rating can indicate where institutional investor sentiment lies; here are seven stocks that analysts love. 
Via InvestorPlace
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
From Merus N.V.
Via GlobeNewswire
Merus' Petosemtamab Abstract Hits Upside Scenario For Overall Response Rate, Duration Of Response: Analyst
 
Via Benzinga
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
From Merus N.V.
Via GlobeNewswire
What To Expect When Merus Presents Petosemtamab Data Update At AACR
 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET 
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.